

Hyperglycemia is the main mediator of prediabetes- and type 2 diabetes-associated impairment of microvascular function: the Maastricht Study

Citation for published version (APA):

Sorensen, B. M., Houben, A. J. H. M., Berendschot, T. T. J. M., Kroon, A. A., Schouten, J. S. A. G., van der Kallen, C. J. H., Henry, R. M. A., Koster, A., Reesink, K. D., Dagnelie, P. C., Schaper, N. C., Schalkwijk, C. G., Schram, M. T., & Stehouwer, C. D. A. (2017). Hyperglycemia is the main mediator of prediabetes- and type 2 diabetes-associated impairment of microvascular function: the Maastricht Study. *Journal of Vascular Research*, 54(Supplement 1), 18-18. <https://doi.org/10.1159/000471944>

DOI:

[10.1159/000471944](https://doi.org/10.1159/000471944)

Document status and date:

Published: 01/01/2017

Document Version:

Publisher's PDF, also known as Version of Record (includes final page, issue and volume numbers)

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.tue.nl/taverne

Take down policy

If you believe that this document breaches copyright please contact us at:

openaccess@tue.nl

providing details and we will investigate your claim.

Methods: People with (DM=210) and without (NoDM=117) Type 2 diabetes had GFR (Cockcroft-Gault) and AER (overnight urine collection) measured. Plasma biomarkers [MMP1, MMP3, MMP7, MMP10 and MMP12] were measured on OLINK proteomics platform.

Results: MMP3, MMP7, MMP10 were associated with GFR in DM but not in NoDM [For DM, Adjusted Standardised Beta (StdBeta) -0.324(p<0.001), -0.251(p<0.001) and -0.178 (p=0.002) respectively], independently of potential confounders (age, sex, blood pressure, BMI, cholesterol and HbA_{1c}). There was an interaction between presence/absence of diabetes and MMP3 (p=0.007). AER was associated with MMP7, independently of confounders, in DM but not in NoDM [For DM Adjusted StdBeta 0.266(p<0.001)]. All other biomarkers were not associated with GFR or AER.

Conclusion: Decreasing GFR is associated with increasing MMPs in DM but not in NoDM. Increasing AER is associated with increasing levels MMP7 in DM but not in NoDM. These results suggest MMPs may play a role in diabetic renal complications.

PoA-19

Hyperglycemia is the Main Mediator of Prediabetes- and Type 2 Diabetes-Associated Impairment of Microvascular Function: The Maastricht Study

B. M. Sørensen¹, A. J.H.M. Houben², T. T.J.M. Berendschot³, A. A. Kroon², J. S.A.G. Schouten³, C. J.H. van der Kallen², R. M.A. Henry², A. Koster⁴, K. D. Reesink⁵, P. C. Dagnelie⁶, N. C. Schaper², C. G. Schalkwijk², M. T. Schram², C. D.A. Stehouwer²

¹Internal medicine, Maastricht University, Netherlands, ²Internal Medicine, Maastricht University, Netherlands, ³University Eye Clinic Maastricht, Maastricht University Medical Center+, Netherlands, ⁴Department of Social Medicine, Maastricht University, Netherlands, ⁵Department of Biomedical Engineering, Maastricht University, Netherlands, ⁶Department of Epidemiology, Maastricht University, Netherlands

Introduction: Prediabetes- and type 2 diabetes-associated microvascular dysfunction may explain their increased risk of microvascular complications. Mechanisms underlying microvascular dysfunction in (pre)diabetes remain poorly understood. We investigated to what extent differences in retinal and skin microvascular function between individuals without and with (pre)diabetes are potentially attributable to hyperglycemia, insulin resistance, blood pressure, lipid profile and low-grade inflammation.

Methods: In The Maastricht Study, a type 2 diabetes-enriched population-based cohort study (n=1791, 51% men, aged 60±8 years), we determined flicker light-induced retinal arteriolar %-dilation (Dynamic Vessel Analyzer), heat-induced skin %-hyperemia (laser-Doppler flowmetry) and diabetes status (OGTT; normal glucose metabolism (NGM), (n=1040), prediabetes (n=276) or type 2 diabetes (n=475)). Composite indices were formed of hyperglycemia, insulin resistance, blood pressure, lipid profile, and low-grade inflammation. Mediating effects of composite indices on prediabetes- and type 2 diabetes-associated microvascular dysfunction were estimated by linear regression.

Results: Age- and sex-adjusted analyses showed lower retinal arteriolar %-dilation in prediabetes (B=-0.16, 95%CI [-0.53;0.21]), with further deterioration in type 2 diabetes (B=-0.83 [-1.15;-0.51]) versus NGM, p-trend<0.001. Skin %-hyperemia was lower in prediabetes (B=-80

[-198;38]), with further deterioration in type 2 diabetes (B=-210 [-309;-112]) versus NGM, p-trend<0.001. Type 2 diabetes-associated differences in microvascular function were explained mainly by hyperglycemia (mediating effect [bootstrapped 95%CI] 55.3% [20.4%;91.3%] and 64.8% [6.2%;122.4%], respectively). Other composite indices did not significantly contribute. Patterns of mediation were similar for prediabetes-associated microvascular dysfunction.

Conclusions: Our findings suggest early and intensive glycemic control in (pre)diabetes as a promising therapeutic target for the prevention of (pre)diabetes-associated microvascular complications.

PoA-20

Type 1 Diabetes Increases Retention of Low-Density Lipoprotein at Atherosclerosis-Susceptible Sites in the Mouse Vasculature.

Lasse Bach Steffensen¹, Mette Kallestrup Hagensen², Martin Bødtker Mortensen², Mads Kjøelby³, Ninna Stillits⁴, Jacob Fog Bentzon²

¹University of Southern Denmark, ²Atherosclerosis Research Unit, Institute of Clinical Medicine and Department of Cardiology, Aarhus University Hospital, Skejby, Denmark, ³Danish Diabetes Academy, Department of Biomedicine, Aarhus University, Aarhus, Denmark., ⁴Atherosclerosis Research Unit, Institute of Clinical Medicine and Department of Cardiology, Aarhus University Hospital, Skejby, Denmark.

Introduction: Individuals with type 1 diabetes are at high risk of developing atherosclerotic cardiovascular disease. However, comprehensive knowledge of the underlying mechanism is lacking. Increased retention of low-density lipoprotein (LDL) at atherosclerosis-susceptible sites has been suggested to accelerate atherogenesis in type 1 diabetic individuals. The aim of the present study was to test this hypothesis by investigating whether retention of LDL is increased in atherosclerosis-susceptible sites in a mouse model of type 1 diabetes.

Methods: Fluorescently-labeled LDL from healthy non-diabetic human individuals was intravenously injected into type 1 diabetic Ins2(Akita) mice and non-diabetic wildtype littermates. The amount of retained LDL 24 hours post-injection was quantified by fluorescence microscopy of cryosections of the atherosclerosis-susceptible inner curvature of the aortic arch, and by scans of thoracic aorta en face preparations. Vascular gene expression in the inner curvature of the aortic arch was analyzed by microarray and quantitative polymerase chain reaction.

Results: LDL retention was detected at atherosclerosis-prone sites of the aortic arch and located in both intimal and medial layers. Quantitative microscopy revealed a 8.1-fold increase in retained LDL in Ins2(Akita) mice compared to wildtype littermates. These findings were confirmed in independent experiments using near-infrared scans of thoracic aorta en face preparations. However, diabetic status did not affect expression of genes known to be involved in LDL retention.

Conclusion: Experimental type 1 diabetes increases the ability of the vascular wall to retain LDL. This effect may contribute to the increase in atherosclerotic cardiovascular disease observed in type 1 diabetic patients.